18 Jul Atopic Dermatitis: Mount Sinai Study Finds Lebrikizumab May Allow Longer Intervals Between Treatments
MedicalResearch.com Interview with:
Emma Guttman-Yassky, M.D., PhD,
Lead investigator of this study
Waldman Professor and
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai, NY
MedicalResearch.com: What is the background for this study?
Response: The idea to test how spacing out treatment or even stopping it affects treatment responses once patients are well controlled. Lebrikizumab it is a potent biologic agent with a relatively long-lasting effect.
MedicalResearch.com: What are the main findings?
- Patients that were well controlled by lebrikizumab at week 16 on four different things trials were evaluated for maintenance of response on every two or four weeks or off drug (in the mono-therapy trials) and every two and four weeks in the add on TCS studies.
- The results showed maintenance of response throughout the follow up period of up to one year regardless of dosing regimen (both the every two-weeks and every four weeks showed similar maintenance of response overtime.) Further, a large proportion of patients achieving response at week 16 could also be maintained off drug for the follow up period.
MedicalResearch.com: What should readers take away from your report?
Response: For patients that achieve good disease control and clearance it may be possible to space out administration of the drug to every 4 weeks and perhaps even more in certain situations.
MedicalResearch.com: What recommendations do you have for future research as a results of this study?
Response: Future research should clarify if any patient subset showed particularly better responses and biomarkers related to better responses that can identify the super responders to this and other treatments.
Disclosures: I was an investigator on the trial.
Maintenance of efficacy and safety with lebrikizumab up to one year of treatment in patients with moderate-to-severe atopic dermatitis with or without topical corticosteroids
(LB05) – Late-Breaker Session -Presentation at 25th World Congress of Dermatology
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on July 18, 2023 by Marie Benz MD FAAD